Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17232433 | 0.90 | GSTP1 (0.51) | GSTP1GSTM2 | |
| SCHEMBL14959168 | 0.89 | GSTP1 (0.64) | GSTP1GSTM2 | |
| SCHEMBL26425058 | 0.88 | GSTP1 (0.64) | GSTP1GSTM2 | |
| SCHEMBL26424984 | 0.80 | IDO1 (0.58) | GSTP1GSTM2 | |
| SCHEMBL17232453 | 0.80 | GSTP1 (0.52) | GSTP1GSTM2 | |
| SCHEMBL3502370 | 0.79 | GSTP1 (0.74) | GSTP1GSTM2 | |
| SCHEMBL26424615 | 0.78 | GSTP1 (0.55) | GSTP1GSTM2 | |
| SCHEMBL300204 | 0.77 | GSTP1 (0.82) | GSTP1GSTM2 | |
| SCHEMBL13997681 | 0.76 | GSTP1 (0.66) | GSTP1GSTM2 | |
| SCHEMBL13906505 | 0.76 | GSTP1 (0.76) | GSTP1GSTM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128972-A1 | Anat Inhibitors and Methods of Use Thereof | Atomwise Inc. | 2023-04-27 | — | — | US | disclosed |
| US-9757375-B2 | Compounds that inhibit human DNA ligases and methods of treating cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-09-12 | — | — | US | disclosed |
| US-9073896-B2 | Compounds that inhibit human DNA ligases and methods of treating cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2015-07-07 | — | — | US | disclosed |
| US-20140113891-A1 | Compounds that inhibit human DNA ligases and methods of treating cancer | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-04-24 | — | — | US | disclosed |
| US-8445537-B2 | Compounds that inhibit human DNA ligases and methods of treating cancer | STC.UNM (US) | 2013-05-21 | — | — | US | disclosed |
| US-20120122896-A1 | 2,1,3-BENZOXADIAZOL DERIVATIVES FOR THE INHIBITION OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | PIKE PHARMA GMBH (CH) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128972-A1 | Anat Inhibitors and Methods of Use Thereof | AANAT, CHAT, NAT1 | GSTP1 624/4885GSTM2 510/4885 |
| US-20120122896-A1 | 2,1,3-BENZOXADIAZOL DERIVATIVES FOR THE INHIBITION OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TENT4B, IRF3, MAVS | GSTP1 1679/4885GSTM2 2265/4885 |
| US-20140113891-A1 | Compounds that inhibit human DNA ligases and methods of treating cancer | LIG1, LIG4, LIG3 | GSTP1 2223/4885GSTM2 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.